422 related articles for article (PubMed ID: 7686362)
1. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
2. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
3. Analysis of NK cell activity, lymphocyte reactivity to mitogens and serotest PSA and TPS values in patients with primary and disseminated prostate cancer, PIN and BPH.
Kastelan M; Kovacić K; Tarle R; Kraljić I; Tarle M
Anticancer Res; 1997; 17(3B):1671-5. PubMed ID: 9179216
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
5. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
6. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
Morote Robles J; de Torres Mateos JA
Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
[TBL] [Abstract][Full Text] [Related]
7. Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.
Kraljić I; Kovacić K; Tarle M
Urol Res; 1994; 22(5):329-32. PubMed ID: 7533445
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
9. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
[TBL] [Abstract][Full Text] [Related]
10. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
Tarle M
Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018
[TBL] [Abstract][Full Text] [Related]
11. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
[TBL] [Abstract][Full Text] [Related]
12. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
[TBL] [Abstract][Full Text] [Related]
13. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
Akimoto S; Akakura K; Shimazaki J
Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate.
Barak M; Mecz Y; Lurie A; Gruener N
J Lab Clin Med; 1989 May; 113(5):598-603. PubMed ID: 2469756
[TBL] [Abstract][Full Text] [Related]
15. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer.
Mortarelli EA
Ann Clin Lab Sci; 1992; 22(4):201-6. PubMed ID: 1380223
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
Purnell DM; Heatfield BM; Trump BF
Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
19. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
20. Tissue polypeptide specific antigen serum concentrations in patients with newly diagnosed prostatic diseases.
Wolff JM; Rohde D; Borchers H; Jakse G
Anticancer Res; 2000; 20(6D):5003-5. PubMed ID: 11326658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
